Literature DB >> 17015317

Pharmacodynamics of non-replicating viruses, bacteriocins and lysins.

James J Bull1, Roland R Regoes.   

Abstract

The pharmacodynamics of antibiotics and many other chemotherapeutic agents is often governed by a 'multi-hit' kinetics, which requires the binding of several molecules of the therapeutic agent for the killing of their targets. In contrast, the pharmacodynamics of novel alternative therapeutic agents, such as phages and bacteriocins against bacterial infections or viruses engineered to target tumour cells, is governed by a 'single-hit' kinetics according to which the agent will kill once it is bound to its target. In addition to requiring only a single molecule for killing, these agents bind irreversibly to their targets. Here, we explore the pharmacodynamics of such 'irreversible, single-hit inhibitors' using mathematical models. We focus on agents that do not replicate, i.e. in the case of phage therapy, we deal only with non-lytic phages and in the case of cancer treatment, we restrict our analysis to replication of incompetent viruses. We study the impact of adsorption on dead cells, heterogeneity in adsorption rates and spatial compartmentalization.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17015317      PMCID: PMC1635509          DOI: 10.1098/rspb.2006.3640

Source DB:  PubMed          Journal:  Proc Biol Sci        ISSN: 0962-8452            Impact factor:   5.349


  44 in total

1.  Standardization of pharmacokinetic/pharmacodynamic (PK/PD) terminology for anti-infective drugs.

Authors:  Johan W Mouton; Michael N Dudley; Otto Cars; Hartmut Derendorf; George L Drusano
Journal:  Int J Antimicrob Agents       Date:  2002-04       Impact factor: 5.283

2.  The application of population pharmacokinetic modeling to individualized antibiotic therapy.

Authors:  Alexander A Vinks
Journal:  Int J Antimicrob Agents       Date:  2002-04       Impact factor: 5.283

3.  Use of genetically engineered phage to deliver antimicrobial agents to bacteria: an alternative therapy for treatment of bacterial infections.

Authors:  Caroline Westwater; Laura M Kasman; David A Schofield; Phillip A Werner; Joseph W Dolan; Michael G Schmidt; James S Norris
Journal:  Antimicrob Agents Chemother       Date:  2003-04       Impact factor: 5.191

Review 4.  Novel method to control pathogenic bacteria on human mucous membranes.

Authors:  Vincent A Fischetti
Journal:  Ann N Y Acad Sci       Date:  2003-04       Impact factor: 5.691

5.  Viruses as antitumor weapons: defining conditions for tumor remission.

Authors:  D Wodarz
Journal:  Cancer Res       Date:  2001-04-15       Impact factor: 12.701

6.  Phase II trial of intratumoral administration of ONYX-015, a replication-selective adenovirus, in patients with refractory head and neck cancer.

Authors:  J Nemunaitis; F Khuri; I Ganly; J Arseneau; M Posner; E Vokes; J Kuhn; T McCarty; S Landers; A Blackburn; L Romel; B Randlev; S Kaye; D Kirn
Journal:  J Clin Oncol       Date:  2001-01-15       Impact factor: 44.544

7.  Determination of antibiotic effect in an in vitro pharmacodynamic model: comparison with an established animal model of infection.

Authors:  Charles R Bonapace; Lawrence V Friedrich; John A Bosso; Roger L White
Journal:  Antimicrob Agents Chemother       Date:  2002-11       Impact factor: 5.191

8.  Pharmacodynamics of oritavancin (LY333328) in a neutropenic-mouse thigh model of Staphylococcus aureus infection.

Authors:  Carole J Boylan; Kristina Campanale; Philip W Iversen; Diane L Phillips; Michael L Zeckel; Thomas R Parr
Journal:  Antimicrob Agents Chemother       Date:  2003-05       Impact factor: 5.191

9.  Gene therapy for killing p53-negative cancer cells: use of replicating versus nonreplicating agents.

Authors:  Dominik Wodarz
Journal:  Hum Gene Ther       Date:  2003-01-20       Impact factor: 5.695

10.  Dynamics of success and failure in phage and antibiotic therapy in experimental infections.

Authors:  J J Bull; Bruce R Levin; Terry DeRouin; Nina Walker; Craig A Bloch
Journal:  BMC Microbiol       Date:  2002-11-26       Impact factor: 3.605

View more
  11 in total

Review 1.  Pharmacologically Aware Phage Therapy: Pharmacodynamic and Pharmacokinetic Obstacles to Phage Antibacterial Action in Animal and Human Bodies.

Authors:  Krystyna Dąbrowska; Stephen T Abedon
Journal:  Microbiol Mol Biol Rev       Date:  2019-10-30       Impact factor: 11.056

2.  In vivo growth rates are poorly correlated with phage therapy success in a mouse infection model.

Authors:  J J Bull; G Otto; I J Molineux
Journal:  Antimicrob Agents Chemother       Date:  2011-11-21       Impact factor: 5.191

3.  A tale of tails: Sialidase is key to success in a model of phage therapy against K1-capsulated Escherichia coli.

Authors:  J J Bull; E R Vimr; I J Molineux
Journal:  Virology       Date:  2009-12-16       Impact factor: 3.616

4.  Experimental phage therapy against Staphylococcus aureus in mice.

Authors:  Rosanna Capparelli; Marianna Parlato; Giorgia Borriello; Paola Salvatore; Domenico Iannelli
Journal:  Antimicrob Agents Chemother       Date:  2007-05-21       Impact factor: 5.191

5.  Bacteriophage: laboratorial diagnosis and phage therapy.

Authors:  Joas L Da Silva; Rosario D C Hirata; Mario H Hirata
Journal:  Braz J Microbiol       Date:  2009-09-01       Impact factor: 2.476

Review 6.  Ecology of Anti-Biofilm Agents I: Antibiotics versus Bacteriophages.

Authors:  Stephen T Abedon
Journal:  Pharmaceuticals (Basel)       Date:  2015-09-09

7.  The habits of highly effective phages: population dynamics as a framework for identifying therapeutic phages.

Authors:  James J Bull; Jason J Gill
Journal:  Front Microbiol       Date:  2014-11-18       Impact factor: 5.640

Review 8.  Bacteriophages as Alternatives to Antibiotics in Clinical Care.

Authors:  Danitza Romero-Calle; Raquel Guimarães Benevides; Aristóteles Góes-Neto; Craig Billington
Journal:  Antibiotics (Basel)       Date:  2019-09-04

9.  Phenotypic resistance and the dynamics of bacterial escape from phage control.

Authors:  James J Bull; Christina Skovgaard Vegge; Matthew Schmerer; Waqas Nasir Chaudhry; Bruce R Levin
Journal:  PLoS One       Date:  2014-04-17       Impact factor: 3.240

Review 10.  Phage therapy: eco-physiological pharmacology.

Authors:  Stephen T Abedon
Journal:  Scientifica (Cairo)       Date:  2014-05-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.